Clinical Neuropsychopharmacology and Therapeutics最新文献

The Potential of Probiotics in the Treatment of Schizophrenia 益生菌治疗精神分裂症的潜力

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2021-09-14 DOI: 10.5234/cnpt.12.18

T. Nagamine

引用次数: 1

A Patient with Treatment-resistant Depression Who Achieved Remission with Heated Yoga: A Case Report 难治性抑郁症患者通过热瑜伽获得缓解:一例报告

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2021-08-31 DOI: 10.5234/cnpt.12.12

H. Sakurai, Megha Nagaswami, Emily Tan, Ashley K Meyer, C. Streeter, F. Jain, Simmie L. Foster, A. Yeung, C. Cusin, M. Fava, D. Mischoulon, M. Nyer

{"title":"A Patient with Treatment-resistant Depression Who Achieved Remission with Heated Yoga: A Case Report","authors":"H. Sakurai, Megha Nagaswami, Emily Tan, Ashley K Meyer, C. Streeter, F. Jain, Simmie L. Foster, A. Yeung, C. Cusin, M. Fava, D. Mischoulon, M. Nyer","doi":"10.5234/cnpt.12.12","DOIUrl":"https://doi.org/10.5234/cnpt.12.12","url":null,"abstract":"Novel interventions are needed to manage treatment-resistant depression (TRD), defined as patients who do not respond to two or more antidepressant trials of adequate dose and duration. We report on a 28-year-old female with TRD with nonresponse to several adequate trials of antidepressants who experienced full symptomatic remission after participating in the heated hatha yoga (HY) arm of a randomized controlled trial (RCT) for depression. Patients, including the one of interest, were randomized to 8 weeks of at least twice weekly HY or an 8-week waitlist followed by 8 weeks of HY. HY incorporates yoga plus heat through a se-ries of standardized poses performed in a heated room (105 °Ｆ ). The 30-item Inventory of Depressive Symptoms, Clinician-Rated (IDS-C 30 ) and 28-item Hamilton Depression Rating Scale (HAM-D 28 ) were assessed at key time points throughout the study. The patient attended 16 classes over 8 weeks. Her baseline IDS-C 30 score of 42 decreased to 26 following 2 weeks of HY, and continued declining throughout the intervention, with a final score of 6 (remission) after 8 weeks. HAM-D 28 scores decreased from 26 at baseline to 4 (remission) after 8 weeks. At the 1-month follow-up, the patient’s scores remained stable at 4 on IDS-C 30 and 7 on HAM-D 28 , respectively. HY may serve as a potential intervention for TRD in patients who have not previously responded to conventional antidepressants. The rigorousness of the intervention must be con-sidered regarding recommendations for use in the general population.","PeriodicalId":120512,"journal":{"name":"Clinical Neuropsychopharmacology and Therapeutics","volume":"153 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123260311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Prospects for CNPT CNPT的前景

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2021-06-18 DOI: 10.5234/cnpt.12.11

Hikaru Hori

引用次数: 1

Valproic acid-induced hair color change in an elderly male 丙戊酸致老年男性发色改变

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2021-06-15 DOI: 10.5234/CNPT.12.9

Kensuke Miyazaki, M. Uchiyama

引用次数: 0

Maintenance treatment for schizophrenia during the COVID-19 pandemic: the views of Japanese psychiatrists COVID-19大流行期间精神分裂症的维持治疗:日本精神科医生的观点

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2021-05-31 DOI: 10.5234/CNPT.12.6

Yoshiyo Oguchi, N. Miyake, Kumiko Ando

{"title":"Maintenance treatment for schizophrenia during the COVID-19 pandemic: the views of Japanese psychiatrists","authors":"Yoshiyo Oguchi, N. Miyake, Kumiko Ando","doi":"10.5234/CNPT.12.6","DOIUrl":"https://doi.org/10.5234/CNPT.12.6","url":null,"abstract":"To the editor: Schizophrenia is a chronic, relapsing disease, and one of its most important factors is poor adherence to medication. The patients’ lack of insight and cognitive impairment lead to irregular medication adherence. Additionally, the COVID-19 pandemic has made it difficult for patients to access healthcare [1]. What should be the maintenance treatment for schizophrenia in these situations? First and foremost, we need to consider the maintenance treatment under normal circumstances. Numerous studies have shown that schizophrenic patients with poor medication adherence constitute a prominent group [2]. Furthermore, even patients with good medication adherence can easily show poor medication compliance [3]. Hence, maintenance treatment with long-acting injectable antipsychotics (LAIs) is essential to avoid treatment abandonment, regardless of the situation. Therefore, to investigate Japanese psychiatrists’ views of maintenance treatment for schizophrenia during the COVID-19 pandemic, we conducted a web-based survey of 69/1629 (4.2%) psychiatrists in Japan in October 2020. The participants were psychiatrists (2 women, 67 men; mean age 49.1years, SD=10.2; mean work experience 20.1years, SD=9.7), working in university hospitals (15.9%), general hospitals (14.5%), singledepartment psychiatric hospitals (42.0%), clinics (26.1%) and other (1.5%) throughout Japan. The institutional review board of St. Marinna University School of Medicine Hospital determined that the study was exempt from review.","PeriodicalId":120512,"journal":{"name":"Clinical Neuropsychopharmacology and Therapeutics","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126687802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

A case of hyperprolactinemia and delusion of pregnancy during clozapine treatment 氯氮平治疗中高泌乳素血症伴妊娠妄想1例

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2021-01-14 DOI: 10.5234/CNPT.12.1

K. Onda, Takayuki Yukawa, Emiko Inoue, R. Tsuboya, Masashi Sakaue, T. Someya

引用次数: 2

Agranulocytosis with combination of paliperidone and clozapine: a case report 帕利哌酮与氯氮平联合治疗粒细胞缺乏症1例

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2020-12-25 DOI: 10.5234/cnpt.11.79

S. Dehanov, Mário Santos, P. Gonçalves, T. M. Correia

引用次数: 2

Microbiological Modification Therapy For Acute Medical Presentations Of Generalised Anxiety Disorder 广泛性焦虑障碍急性医学表现的微生物修饰疗法

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2020-11-18 DOI: 10.5234/cnpt.11.67

M. Brzezicki, L. Celentano, M. Ostrowski, A. Chakraborty

{"title":"Microbiological Modification Therapy For Acute Medical Presentations Of Generalised Anxiety Disorder","authors":"M. Brzezicki, L. Celentano, M. Ostrowski, A. Chakraborty","doi":"10.5234/cnpt.11.67","DOIUrl":"https://doi.org/10.5234/cnpt.11.67","url":null,"abstract":"Generalised anxiety disorder (GAD) displays a variety of psychological and physical symptoms. These are difficult to rapidly control with currently available pharmacological options. This review summarises the evidence for an acute use of microbiological modification drugs targeting vagal nerve stimulation. A systematic search was conducted in Medline, Pubmed, and PschInfo for all pre-clinical and human studies concerning the use of Lactobacillus and Bifidobacterium in the treatment of GAD. Twenty-five studies were eligible for inclusion. In mice, modification therapy resulted in improved behav-iour that was at least non-inferior to standard therapy (antidepressants). Brain histopathology revealed further anti-inflammatory and neuroprotective benefits. Vagotomy abolished the anti-GAD properties of the treatment. In humans, several species demonstrated significant reductions in palpitations, shortness of breath, head-aches, flu-like symptoms, and abdominal pains vs. placebo within 4 to 12 weeks. B. bifidum, B. lactis, L. acidophilus and S. thermophiles showed alleviation of physical symptoms to population baseline when added to an antidepressant. No significant side effects were reported in the studies. As physical symptoms are typically the presenting medical complaint of GAD, there is potential to control the disease with the administration of bacteria-containing pharmaceutical agents as an adjunct to current antidepressant options.","PeriodicalId":120512,"journal":{"name":"Clinical Neuropsychopharmacology and Therapeutics","volume":"363 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132282123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relapse of psychiatric symptoms after discontinuation of antipsychotics in pregnant women with schizophrenia: a retrospective study 精神分裂症孕妇停用抗精神病药物后精神症状复发:一项回顾性研究

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2020-10-02 DOI: 10.5234/CNPT.11.61

Ryota Seki, T. Hashimoto, Mami Tanaka, Aiko Sato, H. Kimura, Atsushi Kimura, S. Handa, N. Kanahara, J. Okayama, A. Omoto, M. Endo, Yoshiteru Osone, H. Watanabe, Hirokazu Tanaka, M. Nakazato, M. Shozu, M. Iyo

{"title":"Relapse of psychiatric symptoms after discontinuation of antipsychotics in pregnant women with schizophrenia: a retrospective study","authors":"Ryota Seki, T. Hashimoto, Mami Tanaka, Aiko Sato, H. Kimura, Atsushi Kimura, S. Handa, N. Kanahara, J. Okayama, A. Omoto, M. Endo, Yoshiteru Osone, H. Watanabe, Hirokazu Tanaka, M. Nakazato, M. Shozu, M. Iyo","doi":"10.5234/CNPT.11.61","DOIUrl":"https://doi.org/10.5234/CNPT.11.61","url":null,"abstract":"This study aimed to examine the effect of discontinuation of antipsychotic medication on the relapse of psychiatric symptoms in pregnant women with schizophrenia. We investigated the medical records of all consecutive pregnant women with schizophrenia who continuously visited and delivered their children at Chiba University Hospital from January 2007 to January 2019. We retrospectively assessed the scores on the Clinical Global Impression of Change scale (CGI-C) during the period when psychiatric symptoms changed most during the pregnancy. A CGI-C score of 5 or more was defined as a relapse. Twenty-eight patients consist-ing of the maintained treatment group (n = 18) and the discontinuation group (n= 10) were recruited. During pregnancy, the relapse rate in the maintained treatment group (16.7%) was significantly lower than that in the discontinuation group (90.0%). This study demonstrates a high relapse rate in pregnant women dis-continuing their antipsychotic medication, as well as during the non-pregnancy period. Global Impression of g scale obser v ed d u rin g pre g nanc y","PeriodicalId":120512,"journal":{"name":"Clinical Neuropsychopharmacology and Therapeutics","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129003674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Treatment-resistant depression and clinical implications of its association with comorbid anxiety disorders 难治性抑郁症及其与共病性焦虑症相关的临床意义

Clinical Neuropsychopharmacology and Therapeutics Pub Date : 2020-09-15 DOI: 10.5234/CNPT.11.54

M. Ichiki, Jiro Masuya, Takeshi Inoue

{"title":"Treatment-resistant depression and clinical implications of its association with comorbid anxiety disorders","authors":"M. Ichiki, Jiro Masuya, Takeshi Inoue","doi":"10.5234/CNPT.11.54","DOIUrl":"https://doi.org/10.5234/CNPT.11.54","url":null,"abstract":"Childhood abuse, trait anxiety, and neuroticism are associated with depression, and activation of the amygdala has been hypothesized as the biological basis of these predisposing factors. Anxiety disorder often coexists with major depressive disorder, and this comorbidity has been postulated to occur owing to the above predisposing factors. However, this possibility has not yet been fully confirmed in clinical studies. A history of childhood abuse, and anxiety disorder or anxiety symptoms have been reported to coexist in patients with treatment-resistant depression. Therefore, the above hypothesis may also apply to treatment-resistant depression. Large-scale studies are needed to test whether childhood abuse, propensity for trait anxiety/neuroticism, amygdala activation, and the coexistence of anxiety disorder/anxiety symptoms are more pronounced in patients with treatment-resistant depression than those with non-treatment-resistant depression. At present, it is clinically clear that treatment-resistant depression more frequently occurs in patients with comorbid anxiety disorders and a history of childhood abuse. The clinical care of patients with treatment-resistant depression keeping this information in mind may lead to a better understanding of these patients, and may also assist in the development of effective treatment strategies.","PeriodicalId":120512,"journal":{"name":"Clinical Neuropsychopharmacology and Therapeutics","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116584448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0